PRLD241220P7500
- 2.45
- 0.000.00%
Prelude Therapeutics Newsroom
Prelude Therapeutics (PRLD) Gets a Sell From Morgan Stanley
Morgan Stanley Maintains Prelude Therapeutics(PRLD.US) With Sell Rating
JMP Securities Maintains Prelude Therapeutics(PRLD.US) With Buy Rating, Cuts Target Price to $4
Prelude Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Prelude Therapeutics Analyst Ratings
Barclays Maintains Prelude Therapeutics(PRLD.US) With Sell Rating, Maintains Target Price $1
Prelude Therapeutics (PRLD) Receives a Sell From Barclays
JMP Securities Maintains Prelude Therapeutics(PRLD.US) With Buy Rating, Maintains Target Price $7
Prelude Therapeutics Analyst Ratings
H.C. Wainwright Maintains Prelude Therapeutics(PRLD.US) With Buy Rating, Maintains Target Price $5
Barclays Maintains Prelude Therapeutics(PRLD.US) With Sell Rating, Maintains Target Price $1
Barclays Maintains Prelude Therapeutics(PRLD.US) With Sell Rating, Cuts Target Price to $1
Cautious Outlook on Prelude Therapeutics: Sell Rating Amid Modest Trial Results and Market Skepticism
JMP Securities Maintains Prelude Therapeutics(PRLD.US) With Buy Rating, Maintains Target Price $7
Buy Rating Affirmed for Prelude Therapeutics Amid Positive Developments in PRT3789 and Strong Financial Position
H.C. Wainwright Upgrades Prelude Therapeutics(PRLD.US) to Buy Rating, Maintains Target Price $5
Prelude Therapeutics Price Target Maintained With a $7.00/Share by JMP Securities
Prelude Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Prelude Therapeutics, Maintains $5 Price Target
H.C. Wainwright Maintains Prelude Therapeutics(PRLD.US) With Hold Rating, Maintains Target Price $5